Aspirin and warfarin versus aspirin monotherapy after myocardial infarction
Document Type
Article
Publication Title
Annals of Pharmacotherapy
Abstract
OBJECTIVE: To review data concerning combined aspirin/warfarin versus aspirin alone for secondary prevention after myocardial infarction (MI). DATA SOURCES: Literature was accessed through MEDLINE (1966-September 2002). Search terms included aspirin, warfarin, secondary prevention, and myocardial infarction. DATA SYNTHESIS: Despite use of low-dose aspirin after an MI, risk of subsequent death and ischemic events remains high, making strategies for secondary prevention imperative. Relevant, large, long-term studies focusing on dual aspirin/warfarin versus aspirin alone in post-MI patients were evaluated. CONCLUSIONS: Aspirin 75-325 mg/d should remain first-line therapy for secondary prevention after MI. Combining aspirin 75-81 mg with warfarin to maintain the international normalized ratio at 2.0-2.5 may provide added benefit, but should be considered only for patients at high risk for thromboembolic events.
First Page
1502
Last Page
1505
DOI
10.1345/aph.1C474
Publication Date
10-1-2003
Recommended Citation
Jeddy, Azzah S. and Gleason, Brenda L., "Aspirin and warfarin versus aspirin monotherapy after myocardial infarction" (2003). Pharmacy Practice Faculty Publications. 602.
https://doi.org/10.1345/aph.1C474
https://collections.uhsp.edu/pharm-practice_pubs/602